CRBP CORBUS PHARMACEUTICALS HLDGS revenue, earnings and financials
For the quarter ended June 30, 2026, CORBUS PHARMACEUTICALS HLDGS reported revenue of n/a, net income of −$35.0M and diluted EPS of −$1.81; for the fiscal year ended December 2025 revenue was n/a.
CRBP annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$85.3M, net income −$78.5M (margin n/a), EPS −$5.90
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$48.7M, net income −$40.2M (margin n/a), EPS −$3.68
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$45.1M, net income −$44.6M (margin n/a), EPS −$10.31
- Fiscal year ended Dec 2022: revenue $0, gross profit n/a, operating income −$39.8M, net income −$42.3M (margin n/a), EPS −$10.15
- Fiscal year ended Dec 2021: revenue $882K, gross profit n/a, operating income −$56.0M, net income −$45.6M (margin -5176.4%), EPS −$11.15
CRBP quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$35.0M, EPS −$1.81
- Quarter ended Mar 31, 2026: revenue n/a, net income −$23.0M, EPS −$1.23
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$20.6M, EPS −$1.17
- Quarter ended Sep 30, 2025: revenue n/a, net income −$23.3M, EPS −$1.90
- Quarter ended Jun 30, 2025: revenue n/a, net income −$17.7M, EPS −$1.44
- Quarter ended Mar 31, 2025: revenue n/a, net income −$17.0M, EPS −$1.39
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$9.53M, EPS −$0.80
- Quarter ended Sep 30, 2024: revenue n/a, net income −$13.8M, EPS −$1.15
- Quarter ended Jun 30, 2024: revenue n/a, net income −$10.00M, EPS −$0.90
- Quarter ended Mar 31, 2024: revenue n/a, net income −$6.90M, EPS −$0.83
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$8.02M, EPS −$1.75
- Quarter ended Sep 30, 2023: revenue n/a, net income −$10.1M, EPS −$2.27
- Quarter ended Jun 30, 2023: revenue n/a, net income −$8.78M, EPS −$2.05
- Quarter ended Mar 31, 2023: revenue n/a, net income −$17.7M, EPS −$4.24
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$10.9M, EPS −$2.60
- Quarter ended Sep 30, 2022: revenue $0 (down 100.0% year over year), net income −$8.78M, EPS −$2.11
- Quarter ended Jun 30, 2022: revenue n/a, net income −$13.2M, EPS −$3.18
- Quarter ended Mar 31, 2022: revenue $0 (down 100.0% year over year), net income −$9.44M, EPS −$2.26
- Quarter ended Dec 31, 2021 (from the annual report): revenue $0, net income −$10.3M, EPS −$10.84
- Quarter ended Sep 30, 2021: revenue $97.3K, net income −$2.18M, EPS −$0.02
CRBP cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$64.5M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$41.8M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$36.1M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$37.5M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$48.2M, share buybacks n/a
CRBP balance sheet
- Jun 30, 2026: cash $23.4M, total assets $127M, total liabilities $24.7M, shareholders' equity $102M
- Mar 31, 2026: cash $25.7M, total assets $144M, total liabilities $18.1M, shareholders' equity $126M
- Dec 31, 2025: cash $28.5M, total assets $168M, total liabilities $20.7M, shareholders' equity $148M
- Sep 30, 2025: cash $27.0M, total assets $110M, total liabilities $17.4M, shareholders' equity $92.1M
- Jun 30, 2025: cash $20.0M, total assets $125M, total liabilities $14.1M, shareholders' equity $111M
- Mar 31, 2025: cash $18.9M, total assets $140M, total liabilities $12.8M, shareholders' equity $127M
- Dec 31, 2024: cash $17.2M, total assets $156M, total liabilities $13.5M, shareholders' equity $142M
- Sep 30, 2024: cash $19.4M, total assets $164M, total liabilities $13.7M, shareholders' equity $150M
Is CRBP profitable?
No. CORBUS PHARMACEUTICALS HLDGS lost $102M over the last four quarters.
What is CRBP's EPS?
Diluted earnings per share over the last four quarters were −$6.11; −$1.81 in the latest quarter.